In pharmaceutical manufacturing, a batch can spend hours being processed and weeks waiting. The materials may be available, the equipment may be capable, and the laboratory may be highly skilled: yet the product still remains in quarantine, queue, review, or approval status.
Value stream mapping exposes this gap.
A value stream map connects material flow with information flow across the complete GMP journey: raw material receipt, sampling, testing, dispensing, tablet production, packaging, quality control, quality assurance, and release-for-sale. It does not merely document manufacturing steps. It shows where the batch waits, where information is delayed, and where formal approvals create constraints.
The objective is not to remove necessary GMP controls. It is to design a safer, more predictable flow around them.
Value stream mapping is the Lean method of visualising every material and information-flow activity required to bring a product from its starting point to the customer. The Lean Enterprise Institute’s VSM guidance distinguishes between the current state and the future state: the actual flow and the intended flow.
1. Select the Right Pharmaceutical Value Stream
Begin with a product family, not an entire factory.
For this worked example, assume a solid-dose oral tablet line producing a 1,000,000-tablet batch. The selected product follows a stable route:
- Raw material receipt and quarantine
- Sampling and raw material QC release
- Dispensing and weighing
- Granulation
- Blending
- Tablet compression
- Film coating
- Primary and secondary packaging
- Finished-product QC testing
- QC review
- QA batch record review
- Release-for-sale decision
The scope begins when raw materials arrive at the site and ends when the batch status changes to Released in the ERP or quality system.
That boundary matters. If the map stops at packaging, it misses the very queues that often determine the customer lead time: laboratory testing, documentation, deviation management, and QA approval.
A cross-functional mapping team should include:
- Manufacturing and packaging operators
- Warehouse and materials planning
- QC laboratory representatives
- QA reviewers
- Engineering or maintenance
- Supply chain and customer service
- A Lean Six Sigma facilitator
Capture the Voice of the Customer, the Voice of the Business, and the Voice of the Process. For example:
- Customer requirement: reliable supply within 14 calendar days
- Business requirement: five released batches per month
- Process reality: batches currently take more than 27 days to release
2. Build the Current-State Value Stream Map
The current-state map should reflect what actually happens: not what the procedure says should happen.
Walk the process physically and collect timestamps from batch records, laboratory systems, MES, ERP transactions, and QA logs. Record:
- Processing or cycle time
- Queue and waiting time
- Work in process
- Batch size and inventory
- First Pass Yield
- Rework and deviation frequency
- Handoffs and approval points
- Equipment availability and changeover time
A map without numbers is only a diagram. A data-supported map reveals the relationship between cycle time, lead time, throughput, takt time, and inventory.
For this example, monthly demand is five batches and the site has 20 available working days per month:
[
\text{Takt Time} = \frac{20 \text{ working days}}{5 \text{ batches}} = 4 \text{ days per batch}
]
The value stream must therefore release approximately one batch every four working days to meet demand.
3. Worked Current-State Example: The 27-Day Batch
The following figures are illustrative but representative of the type of data a pharmaceutical VSM team may collect.
| Process step | Processing time | Waiting before step | Batch inventory or queue |
|---|---|---|---|
| Raw material receipt and quarantine | 4 hours | 96 hours | 8 batches |
| Sampling and material QC release | 16 hours | 72 hours | 3 batches |
| Dispensing | 6 hours | 24 hours | 2 batches |
| Granulation | 10 hours | 16 hours | 1 batch |
| Blending | 8 hours | 12 hours | 1 batch |
| Compression | 12 hours | 20 hours | 1 batch |
| Coating | 10 hours | 18 hours | 1 batch |
| Packaging | 14 hours | 24 hours | 2 batches |
| Finished-product QC testing | 36 hours | 96 hours | 4 batches |
| QC review | 8 hours | 48 hours | 2 batches |
| QA review and release | 12 hours | 96 hours | 3 batches |
| Total | 136 hours | 522 hours | 28 batch equivalents |
The current-state calculation is:
- Value-adding and necessary processing time: 136 hours
- Waiting and queue time: 522 hours
- Total lead time: 658 hours, or approximately 27.4 calendar days
- Processing-to-lead-time ratio: 20.7%
- Average WIP: 28 batch equivalents
- Finished-product QC and QA waiting: 240 hours combined
The key observation is clear: the process is not primarily constrained by tablet compression or coating. The most significant delays occur around material release, finished-product testing, QC review, and QA approval.
This is where the Theory of Constraints becomes useful. The constraint is the step limiting overall flow. In this example, the laboratory and release system: not the tablet press: is the dominant constraint.
4. Identify the Eight DOWNTIME Wastes
The eight Lean wastes, often remembered as DOWNTIME, appear in both physical and administrative activities.
- Defects: Documentation errors, missing signatures, incorrect sample labels, or repeat testing.
- Overproduction: Producing batches before downstream QC or QA capacity is available.
- Waiting: Samples waiting for HPLC availability, batch records waiting for review, or materials waiting in quarantine.
- Non-utilized talent: Analysts and operators spending specialist time searching for records or correcting avoidable paperwork.
- Transportation: Moving samples, paper records, and materials between distant departments.
- Inventory: Excess raw materials, packaging components, intermediate product, and finished batches awaiting release.
- Motion: Repeated movement between production areas, offices, archives, and laboratory stations.
- Extra-processing: Duplicate data entry, serial reviews that add no new risk control, or repeated reconciliation of the same information.
Approval is a necessary governance mechanism, but it can become a bottleneck when every document must move through multiple serial checkpoints. The correct question is not, “How do we remove approval?” It is, “How do we make approval risk-based, complete, and available when the batch is ready?”
5. Design the Future-State Map
The future state should preserve GMP compliance while reducing avoidable delay.
Potential design principles include:
-
Create a pacemaker process.
Use a levelled packaging or production schedule to release work at a controlled rate rather than sending large batches into the system. -
Introduce a visual QC queue.
Prioritise samples by batch readiness, stability, expiry risk, and customer demand. A visual management board or Andon-style signal can alert teams when a sample exceeds its service-level target. -
Schedule laboratory capacity against takt.
If the system must release one batch every four days, testing capacity must support that rhythm. Instrument availability, analyst allocation, and method sequencing should be planned accordingly. -
Move suitable reviews in parallel.
Where permitted by the pharmaceutical quality system, QA can prepare documentation review while QC testing is progressing rather than waiting for every record to arrive at the end. -
Standardise batch documentation.
Use clear templates, right-first-time checks, electronic workflows where validated, and defined escalation rules for missing information. -
Control WIP with a pull signal.
Establish practical limits for batches waiting for QC, QC review, and QA release. Work should enter the next stage when capacity is available: not simply because the previous stage has completed. -
Use Autonomation carefully.
Intelligent systems can detect missing fields, overdue samples, incorrect status codes, or abnormal process signals in real time. These alerts should support human decision-making and remain within validated system controls.
6. Current State Versus Future State
The following future-state targets assume validated process changes, approved procedures, appropriate training, and no reduction in required testing or release standards.
| Metric | Current state | Future state target | Improvement |
|---|---|---|---|
| End-to-end lead time | 658 hours | 275 hours | 58.2% reduction |
| Processing time | 136 hours | 123 hours | 9.6% reduction |
| Waiting and queue time | 522 hours | 152 hours | 70.9% reduction |
| WIP inventory | 28 batch equivalents | 15 batch equivalents | 46.4% reduction |
| Finished QC queue | 96 hours | 24 hours | 75.0% reduction |
| QA review queue | 96 hours | 16 hours | 83.3% reduction |
| First Pass Yield | 94.5% | 98.5% | 4.0 percentage-point gain |
| Release cadence | One batch every 8.2 days | One batch every 4 days | Aligned to takt |
The future-state design does not depend on one large technology project. It combines scheduling discipline, visual management, standard work, capacity balancing, error prevention, and improved information flow.
7. Sequence the Kaizen Work
Do not launch every improvement simultaneously. Sequence the work according to customer impact, constraint relief, risk, and implementation readiness.
Wave 1: Stabilise and see the flow
- Confirm the current-state data
- Define standard timestamps
- Create a daily batch-release board
- Establish WIP limits
- Track overdue QC samples and QA reviews
- Clarify ownership for every handoff
Wave 2: Improve QC laboratory flow
- Analyse sample arrival patterns
- Level HPLC and analyst workloads
- Reduce avoidable instrument changeovers
- Standardise sample login and prioritisation
- Establish a rapid escalation path for overdue testing
Wave 3: Improve documentation and approval
- Pareto recurring documentation errors
- Apply right-first-time checks at the point of completion
- Separate routine review from exception review
- Run suitable QA activities in parallel
- Define clear approval service-level targets
Wave 4: Sustain and control
- Monitor lead time, throughput, WIP, FPY, deviations, and release performance
- Use control charts for critical process metrics
- Audit the future-state standard work
- Re-map the value stream after major product, equipment, or regulatory changes
- Review benefits at 30, 60, and 90 days
Build Capability Through Lean Six Sigma Certification
Value stream mapping in pharmaceutical manufacturing requires more than drawing process boxes. It requires the ability to define scope, collect reliable data, identify the true bottleneck, distinguish necessary control from avoidable delay, and lead improvement without compromising product quality or patient safety.
A Lean Six Sigma Green Belt course is well suited to professionals who support or lead cross-functional improvement projects. For complex, enterprise-level pharmaceutical transformations, Black Belt training develops deeper capability in statistical analysis, project leadership, root-cause investigation, and control planning.
At Lean 6 Sigma Hub, the online training approach is self-paced, practical, and CSSC-accredited, with case studies, worked examples, project tools, and real-world simulations.
Start your Lean Six Sigma certification journey and learn to turn pharmaceutical batch flow into measurable, compliant, customer-focused performance.
Kaizen. Kai-Care. Kai-Done. ( Lean Six Sigma)
